Remove 2026 Remove Competition Remove Physicians
article thumbnail

Consequences of the First 10 Drugs Selected for Medicare’s Negotiation Program

PM360

They do not have biosimilar or generic competition available in the market. The MFPs will be announced publicly in September 2024 and go into effect on January 1, 2026. Additionally, highly competitive classes, such as rapid-acting insulin and immunologics are included on the selected drug list.

article thumbnail

Five points on CMS’s first ten picks for price negotiations

Clarivate

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. exclusions exist for orphan drug designation and biosimilar competition ).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

U.S. market access landscape: A push for control is erasing the boundary between payers and providers in U.S. healthcare

Clarivate

Oak Street has 169 locations across 21 states and expects to nearly double its size to 300 centers by 2026. VillageMD’s rollup continued with a March 3 announcement that it was acquiring Starling Physicians, a Connecticut-based physician group, expanding its footprint to 680 practice locations in 26 markets.

article thumbnail

Two Key Questions About Payer Strategies in 2023

PM360

However, we expect drugs without strong therapeutic alternatives to have an advantage in negotiations, while drugs in highly competitive classes will be negotiating from a weaker position. Expect the nine competitors to explore Kotler’s 4Ps of Marketing to gain share in this lucrative and competitive marketplace.

article thumbnail

T2D market growth driven by novel GLP-1RAs and once-weekly basal insulin therapies

Pharmaceutical Technology

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

article thumbnail

How retailers and “payviders” are disrupting U.S. healthcare in 2024

Clarivate

Humana is following a similar growth strategy as it sharpens competition with UnitedHealthcare in the Medicare Advantage sector. CVS expects to accelerate Oak Street’s footprint expansion in coming years, with previously stated plans of having more than 300 centers in total by 2026. Source: News reports and company releases.

Retail 52
article thumbnail

Pulsed field ablation re-energizes the atrial fibrillation market

Clarivate

Increased appeal for dual-energy systems: Sometimes a situation calls for RF, but physicians like the ease and efficiency of PFA. FDA approval in the fourth quarter, with Johnson & Johnson’s Varipulse system close behind, so competition will pick up. Abbott’s Volt should join the party in early 2026.